Skip to main content

Table 1 The clinical characteristics of enrolled patients stratified by pathological results between April 2016 and March 2020

From: Development and head-to-head comparison of machine-learning models to identify patients requiring prostate biopsy

Clinical characteristics

PCa (GS ≥ 3 + 3)

CSPCa (GS ≥ 3 + 4)

No (n = 443)†

Yes (n = 245)†

P

No (n = 488)†

Yes (n = 200)†

P

Age (years)

66 (61–72)

70 (63–76)

< 0.001

66 (61–72)

70 (63–76)

< 0.001

tPSA (ng/ml)

10.5 (6.65–17.0)

20.8 (9.67–30.3)

< 0.001

10.9 (6.70–17.1)

23.0 (10.9–33.1)

< 0.001

f/tPSA

0.15 (0.10–0.21)

0.11 (0.07–0.17)

< 0.001

0.15 (0.10–0.21)

0.11 (0.07–0.17)

< 0.001

PSAD (ng/ml2)

0.18 (0.11–0.29)

0.46 (0.25–0.73)

< 0.001

0.19 (0.11–0.30)

0.52 (0.30–0.80)

< 0.001

PV (ml)

58 (39–82)

38 (27–58)

< 0.001

57 (38–81)

37 (27–54)

< 0.001

MRI-PCa, No. (%)

  

< 0.001

  

< 0.001

 Negative

250 (56)

37 (15)

 

264 (54)

23 (12)

 

 Equivocal

95 (21)

29 (12)

 

104 (21)

20 (10)

 

 Suspicious

98 (22)

179 (73)

 

120 (25)

157 (79)

 

MRI-SVI, No. (%)

  

< 0.001

  

< 0.001

 Negative

439 (99)

163 (67)

 

481 (99)

121 (61)

 

 Equivocal

1 (0.2)

7 (3)

 

1 (0.2)

7 (4)

 

 Suspicious

3 (0.7)

75 (31)

 

6 (1)

72 (36)

 

MRI-LNI, No. (%)

  

< 0.001

  

< 0.001

 Negative

432 (98)

202 (82)

 

475 (97)

159 (80)

 

 Equivocal

11 (2)

18 (7)

 

12 (2)

17 (9)

 

 Suspicious

0 (0)

25 (10)

 

1 (0.2)

24 (12)

 
  1. PCa prostate cancer, CSPCa clinically significant prostate cancer, GS Gleason score, tPSA total prostate-specific antigen, f/tPSA free/total PSA, PV prostate volume, SVI seminal vesicle invasion, LNI lymph node invasion
  2. †Data are presented as median (quartile range) unless other indicated
Back to article page

BMC Urology

ISSN: 1471-2490

Contact us